Paritaprevir
CAY-28301-25 25 mg
Data Sheet: 
SDS:
SDS:
CAS
1216941-48-8
Formulation
A solid
Purity
≥98%
MW
765,9
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
Paritaprevir is an orally bioavailable, direct-acting inhibitor of the hepatitis C virus (HCV) non-structural 3/4A (NS3/4A) serine protease.{45394} It inhibits HCV replication in stable Huh7-derived replicon cell lines infected with subgenomic genotypes 1a, 1b, 2a, 3a, 4a, and 6a (EC50s = 1, 0.21, 5.3, 19, 0.09, and 0.69 nM, respectively). It also inhibits replicons from clinical isolates of genotypes 1a (EC50s = 0.43-1.87 nM) and 1b (EC50s = 0.033-0.087 nM). Formulations containing paritaprevir in combination with ombitasvir, ritonavir, and dasabuvir with and without ribavirin have been used in the treatment of chronic HCV genotype 1 infection.
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
